Navigation Links
Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee
Date:6/8/2011

tion against Parkinson's. We look forward to the opportunity to conduct Phase 3 testing, with the goal to bring NLX-P101 to the market for patients in urgent need of a new treatment option."

Drs. During and Kaplitt have been at the forefront of gene therapy research since 1989 and the Phase 2 trial was the culmination of nearly 20 years of progress with their work in gene transfer technology using an adeno-associated virus (AAV) vector (a disabled, non-pathogenic virus). They were the first to demonstrate that AAV could be an effective gene therapy agent in the brain, which they reported in their landmark Nature Genetics paper in 1994. Drs. During, Kaplitt and colleagues subsequently published additional research demonstrating the beneficial effects of AAV-GAD gene therapy for PD in the journal Science in 2002.

About the Phase 2 Study

The trial involved 45 subjects with moderate to advanced PD who were not adequately controlled with current therapies. Medical centers that participated in the study included: Henry Ford Health System; Massachusetts General Hospital; Stanford University School of Medicine; The Feinstein Institute for Medical Research of the North Shore-LIJ Health System; The Ohio State University College of Medicine; University of Colorado School of Medicine; University of Rochester School of Medicine; and Wake Forest University School of Medicine.

Study subjects were randomized to receive either NLX-P101 treatment or sham surgery. Subjects in the NLX-P101 treatment arm received infusions of the genetic material directly into bilateral subthalamic nuclei (STN), a key brain region involved in motor function. Sham-assigned subjects underwent simulation of a bilateral neurosurgical procedure. At the end of each procedure, infusion catheters were removed at the bedside and nothing was left in the brain. All procedures were performed under local anesthesia. All but one of the trial participants were discharg
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. Neurologix Reports Third Quarter 2010 Financial Results
4. Neurologix Completes Additional $7 Million Financing
5. Neurologix Announces First Quarter 2011 Financial Results
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Five MinuteClinic walk-in medical clinics ... metropolitan area. Three clinics opened in Memphis ... A fourth clinic will be added in Springfield ... Bartlett is expected to open October 22.  MinuteClinic is ... the United States . The ...
(Date:9/19/2014)...  Lpath, Inc. (NASDAQ: LPTN ), ... today that it has entered into definitive agreements ... and 3,605,042 unregistered warrants in a registered direct ... share of common stock and one unregistered warrant ... will be $3.475.  The warrants have an exercise ...
(Date:9/19/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... ITCA 650 (continuous subcutaneous delivery of exenatide) in type ... the 50 th Annual Meeting of the European ... the open-label, phase 3 FREEDOM-HBL (high baseline) trial showed ... poorly controlled type 2 diabetes. The results were presented ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... 26, 2007 - A new study published ... ("A National Survey of,Physician-Industry Relationships") on the ... the need for,profession-wide and public policy reforms ... that the existing,voluntary PhRMA (Pharmaceutical Research and ...
... 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced today ... of the Journal of Neuroscience a study,by ... National Jewish,Medical and Research Center demonstrating that ... 11207, demonstrated,neuroprotection in an animal model of ...
Cached Medicine Technology:Ties Between Physicians and Drug Companies Still Too Strong: the,Prescription Project Offers Solutions to Prevent Conflicts of,Interest 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 3
(Date:9/21/2014)... New York, NY (PRWEB) September 21, 2014 ... ( http://www.thegranuflolawsuit.com/ ) have been added over the ... involving claims that allege serious cardiovascular injuries caused ... , A Case List updated on September 15th ... underway in the U.S. District Court, District of ...
(Date:9/21/2014)... 2014 Faculty and staff at Garrison Forest ... in Owings Mills, Md., kicked off the academic year by ... GFS is the first independent school to receive the bands— ... even sleep patterns— as part of a pilot program with ... walking specialty chain. The Vivofit bands are just one tool ...
(Date:9/20/2014)... Recently, UWDress.com, a professional company of ... for its newly announced evening cocktail dresses . ... special occasion outfits are very popular among worldwide customers. ... big savings (up to 65 percent off). , ... fashionable special occasion outfits for the global clients. The ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 The Villa ... Villa del Palmar Cabo San Lucas, Villa La Estancia ... to Hurricane Odile, with plans to welcome guests back ... As of Sept. 19, all members and guests of ... thanks to a coordinated effort with government authorities. ...
(Date:9/20/2014)... CA (PRWEB) September 20, 2014 On ... receive a $250,000 pediatric cancer research grant from Hyundai ... Loma Linda University Children’s Hospital located on 11234 Anderson ... work of Dr. Kimberley Payne, Associate Professor at Loma ... work focuses on leukemia in children. , ...
Breaking Medicine News(10 mins):Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Garrison Forest School Leader in Independent School Wellness Programs 2Health News:Cheap Evening Cocktail Dresses Recently Introduced At UWDress.com 2Health News:Villa Group Resorts in Cabo Largely Unharmed, Plan to Re-open Early October 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3
... 2,500, officials say, but most cases remain mild , , MONDAY, ... swine flu in the United States rose to more than ... the country most affected by the outbreak, according to World ... to the illness rose to three over the weekend, with ...
... 11 MedCath Corporation (Nasdaq: MDTH ... healthcare services, predominately the diagnosis and treatment of ... join its senior management team as Senior Vice ... MedCath hospitals located in Arizona, California, New Mexico ...
... be an invited panelist in the second annual SOA in Healthcare conference ... , ... Plano, Texas (PRWEB) May 11, 2009-- Corepoint Health,s CTO, Dave Shaver, ... conference to be held on June 2 - 4 in Chicago, Illinois. ...
... Hope Solution, a 501-C3 nonprofit organization, is announcing ... telethon at Sojourner-Douglass College , located in Baltimore ... from 12noon to 6pm, and will raise money to ... options and dietary supplements.To view the Multimedia News Release, ...
... Received $22.5 million from the sale of a mortgage ... of debt outstanding under warehouse line in March 2009 ... approximately $46 million.NEW YORK, May 11 Care Investment ... the "Company"), a real estate investment and finance company ...
... MOUNTAIN VIEW, Calif., May 11 Alexza Pharmaceuticals, ... corporate presentation will be webcast live during the Eighth Annual ... 3:30 p.m. Pacific Time. The presentation will be webcast ... access the live presentation via the Web, please go to ...
Cached Medicine News:Health News:U.S. Now Leads World in Swine Flu Cases 2Health News:U.S. Now Leads World in Swine Flu Cases 3Health News:U.S. Now Leads World in Swine Flu Cases 4Health News:U.S. Now Leads World in Swine Flu Cases 5Health News:U.S. Now Leads World in Swine Flu Cases 6Health News:U.S. Now Leads World in Swine Flu Cases 7Health News:U.S. Now Leads World in Swine Flu Cases 8Health News:U.S. Now Leads World in Swine Flu Cases 9Health News:U.S. Now Leads World in Swine Flu Cases 10Health News:U.S. Now Leads World in Swine Flu Cases 11Health News:David Covert to Join MedCath as Senior Vice President, Operations 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 3Health News:Care Investment Trust Inc. Announces First Quarter 2009 Results 2Health News:Care Investment Trust Inc. Announces First Quarter 2009 Results 3Health News:Care Investment Trust Inc. Announces First Quarter 2009 Results 4Health News:Care Investment Trust Inc. Announces First Quarter 2009 Results 5Health News:Care Investment Trust Inc. Announces First Quarter 2009 Results 6Health News:Care Investment Trust Inc. Announces First Quarter 2009 Results 7Health News:Care Investment Trust Inc. Announces First Quarter 2009 Results 8Health News:Care Investment Trust Inc. Announces First Quarter 2009 Results 9Health News:Alexza's Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference 2Health News:Alexza's Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference 3
... and Achilles ruptures are problem enough for your ... care and provide functional treatment for foot and ... you the STORM. A combination of prefabricated brace ... of movement with higher standards of safety. The ...
Provides stability to the ankle by minimizing ankle rotation and prevention of inversion/eversion...
... The Bledsoe PTB Boot is ... alternative to casting for the mid-tibia ... providing patella tendon bearing support. The ... designed for range of motion from ...
The Bledsoe LC & LC2 Boots are our most economical, lightweight walkers. The LC & LC2 are designed to enhance mobility for sprains, strains, and some types of fractures....
Medicine Products: